MichelleAnneBaronMD

PubMed

• 4 citations
  Treatment satisfaction with ITCA 650, a novel drug-device delivering continuous exenatide, versus twice-daily injections of exenatide in type 2 diabetics using metformin
  Robert R. Henry, Julio Rosenstock, John F. McCarthy, Ginger S. Carls, Tom Alessi, John Yee, Michelle A. Baron> ;Diabetes, Obesity & Metabolism. 2018 Mar 1
• 36 citations
  Efficacy and Safety of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Type 2 Diabetes Uncontrolled With Oral Antidiabetes Drugs: The FREEDOM-1 Trial
  Julio Rosenstock, John B. Buse, Rehan Azeem, Prakash Prabhakar, Lise Kjems, Holly Huang, Michelle A. Baron> ;Diabetes Care. 2017 Dec 13
• 56 citations
  Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 d...
  Robert R. Henry, Julio Rosenstock, Douglas Logan, Thomas R. Alessi, Kenneth L. Luskey, Michelle A. Baron> ;Journal of Diabetes and Its Complications. 2014 May 1
• 33 citations
  Randomized Trial of Continuous Subcutaneous Delivery of Exenatide by ITCA 650 Versus Twice-Daily Exenatide Injections in Metformin-Treated Type 2 Diabetes
  Robert R. Henry, Julio Rosenstock, Douglas Logan, Thomas R. Alessi, Kenneth L. Luskey, Michelle A. Baron> ;Diabetes Care. 2013 Sep 1
• A randomized, open-label, multicenter, 4-week study to evaluate the tolerability and pharmacokinetics of ITCA 650 in patients with type 2 diabetes.
  Henry RR, Logan D, Alessi T, Baron MA> ;Clin Ther. 2013-05-01
• 49 citations
  Impact of comorbid conditions and race/ethnicity on glycemic control among the US population with type 2 diabetes, 1988-1994 to 1999-2004.
  Dong-Churl Suh, In-Sun Choi, Craig A. Plauschinat, Jinweon Kwon, Michelle A. Baron> ;Journal of Diabetes and Its Complications. 2010 Nov 1
• 5 citations
  Safety and efficacy of nateglinide/metformin combination therapy in the treatment of type 2 diabetes.
  Marc Israel, Eva Istvan, Michelle A. Baron> ;Vascular Health and Risk Management. 2008 Dec 5
• 24 citations
  Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment-naïve elderly patients with type 2 diabetes.
  S. L. Schwarz, John E. Gerich, A. Marcellari, Lisa Jean-Louis, Das Purkayastha, Michelle A. Baron> ;Diabetes, Obesity & Metabolism. 2008 Aug 1
• 110 citations
  Effects of the Dipeptidyl Peptidase-IV Inhibitor Vildagliptin on Incretin Hormones, Islet Function, and Postprandial Glycemia in Subjects With Impaired Glucose Tolerance
  Julio Rosenstock, James E. Foley, Marc Rendell, Mona Landin-Olsson, Jens J. Holst, Carolyn F. Deacon, Erika Rochotte, Michelle A. Baron> ;Diabetes Care. 2008 Jan 1
• 200 citations
  Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes.
  Julio Rosenstock, Sun Woo Kim, Michelle A. Baron, R.-P. Camisasca, F. Cressier, A. Couturier, Sylvie Dejager> ;Diabetes, Obesity & Metabolism. 2007 Mar 1
• 218 citations
  Comparison of Vildagliptin and Rosiglitazone Monotherapy in Patients With Type 2 Diabetes: A 24-week, double-blind, randomized trial
  Julio Rosenstock, Michelle A. Baron, Sylvie Dejager, David Mills, Anja Schweizer> ;Diabetes Care. 2007 Feb 1
• 86 citations
  PRESERVE-β: Two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin
  John E. Gerich, Philip Raskin, Lisa Jean-Louis, Das Purkayastha, Michelle A. Baron> ;Diabetes Care. 2005 Sep 1
• 15 citations
  Hypoglycemic potential of nateglinide versus glyburide in patients with type 2 diabetes mellitus.
  Vivian Fonseca, David E. Kelley, William T. Cefalu, Michelle A. Baron, Das Purkayastha, John E. Nestler, Shao-Hsuan Hsia, John E. Gerich> ;Metabolism. 2004 Oct 1
• 86 citations
  Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel bloc...
  Kenneth Jamerson, Oliseyenum M. Nwose, Lisa Jean-Louis, Lesley Schofield, Das Purkayastha, Michelle A. Baron> ;American Journal of Hypertension. 2004 Jun 1
• 35 citations
  Efficacy and tolerability of initial combination therapy with nateglinide and metformin in treatment-naïve patients with type 2 diabetes
  Edward S. Horton, James E. Foley, Sharon G. Shen, Michelle A. Baron> ;Current Medical Research and Opinion. 2004 Apr 16
• 4 citations
  Comparison of Repaglinide and Nateglinide in Combination With Metformin: Response to Raskin et al.
  Michelle A. Baron> ;Diabetes Care. 2003 Dec 1
• Join now to see all